Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CNTY-101 in relapsed/refractory CD19-positive B-cell malignancies
NCT05336409Phase 1Terminated
- Sponsor
- Century Therapeutics
- Start
- Jan 2023
- Primary completion
- Jul 2025
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of CNTY-101 in B-cell non-Hodgkin lymphoma (2 arms), sponsored by Century Therapeutics. Primary endpoints: Maximum Tolerated Dose at 28 days and Recommended Phase 2 Regimen at 28 days. Started Jan 2023; status: terminated.
02
Drugs
CNTY-101
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT05336409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05336409.